글로벌 폴리(ADP-리보스) 폴리머라제(PARP) 억제제 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

폴리(ADP-리보스) 폴리머라제(PARP) 억제제 시장 분석

시장은 난소암과 유방암과 같은 암의 발병률이 증가함에 따라 상당한 성장을 경험하고 있으며, 이러한 치료법은 상당한 효능을 보였습니다. Talazoparib, Olaparib, Veliparib를 포함한 PARP 억제제는 암세포 DNA 복구 메커니즘을 표적으로 삼아 종양학에서 필수적입니다. 최근 개발에는 확장된 임상적 지표와 치료 결과를 향상시키는 복합 요법이 포함됩니다. Pfizer, AstraZeneca, Merck와 같은 회사는 혁신적인 제형과 전달 방법에 중점을 두고 연구 개발의 최전선에 있습니다. 시장의 역동성은 규제 승인 증가, 의료 서비스 제공자의 인식 증가, 개인화된 의학의 발전에 영향을 받습니다. 또한 홈 케어 및 온라인 약국 유통 채널로의 전환으로 환자의 접근성이 향상되어 시장 성장이 더욱 촉진되고 있습니다. 전반적으로 PARP 억제제 시장은 지속적인 확장을 앞두고 있으며, 암 치료 옵션 개선에 대한 희망을 제공합니다.

폴리(ADP-리보스) 폴리머라제(PARP) 억제제 시장 규모

글로벌 폴리(adp-리보스) 중합효소(parp) 억제제 시장 규모는 2023년에 89억 7천만 달러로 평가되었으며, 2031년까지 214억 4천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 11.50%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

폴리(ADP-리보스) 폴리머라제(PARP) 억제제 시장 동향

“ 조합 치료에 대한 집중도 증가”

시장은 암 치료의 발전으로 인해 혁신적인 추세를 목격하고 있습니다. 두드러진 추세 중 하나는 PARP 억제제를 다른 암 치료와 함께 사용하여 효능을 높이고 내성을 극복하는 복합 요법에 대한 관심이 높아지는 것입니다. 이 접근 방식은 특히 BRCA 돌연변이가 있는 암을 치료하는 데 적합하여 환자 결과가 개선됩니다. 약물 제형과 전달 메커니즘의 혁신도 등장하여 치료를 더 쉽게 접근하고 효과적으로 만들고 있습니다. 회사는 안전성 프로필과 효능이 향상된 차세대 PARP 억제제를 개발하기 위한 연구에 투자하고 있습니다. 또한 개인 맞춤 의학의 부상으로 치료 프로토콜이 형성되어 치료법이 개별 유전적 프로필에 맞게 조정됩니다. 이러한 추세와 혁신은 PARP 억제제 시장의 강력한 미래를 총체적으로 나타내며 어려운 암에 직면한 환자에게 희망을 높여줍니다.

보고 범위 및 폴리(ADP-리보스) 중합효소(PARP) 억제제 시장 세분화

폴리(ADP-리보스) 폴리머라제(PARP) 억제제 시장 정의

Poly (ADP-Ribose) Polymerase (PARP) inhibitors are a class of drugs designed to target and inhibit the activity of PARP enzymes, which play a crucial role in repairing damaged DNA within cells. By blocking these enzymes, PARP inhibitors prevent cancer cells—especially those with deficiencies in other DNA repair mechanisms, like BRCA mutations—from effectively repairing their DNA, ultimately leading to cell death. These inhibitors are primarily used in the treatment of various cancers, including ovarian and breast cancers, where they have demonstrated significant efficacy. The therapeutic potential of PARP inhibitors continues to expand as research explores their use in combination therapies and additional cancer types, highlighting their importance in modern oncology and personalized medicine.

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Dynamics

Drivers

• Rising Cancer Incidence and Demand for PARP Inhibitors

The increasing rates of ovarian, breast, and prostate cancers are driving significant demand for effective treatment options, positioning Poly (ADP-Ribose) Polymerase (PARP) inhibitors as a pivotal component in modern oncology. According to the National Cancer Institute Ovarian cancer is the fifth most common cause of cancer death in women in the United States. In 2023, there were an estimated 19,710 new cases and 13,270 deaths from the disease. PARP inhibitors specifically target cancer cells with DNA repair deficiencies, such as those caused by BRCA mutations, offering a tailored approach to treatment. As awareness of genetic testing grows, more patients are identified as suitable candidates for PARP inhibition therapy, further fueling its adoption. This increased focus on personalized medicine improves patient outcomes and emphasizes the critical role PARP inhibitors play in addressing these prevalent cancers, thereby driving market growth.

• Advancements in Personalized Medicine

The growing emphasis on personalized treatment plans is a significant market driver for Poly (ADP-Ribose) Polymerase (PARP) inhibitors, particularly for patients with BRCA mutations. These genetic mutations increase susceptibility to certain cancers, making targeted therapies like PARP inhibitors especially effective. By specifically inhibiting the PARP enzyme, these drugs disrupt the DNA repair process in cancer cells, leading to cell death. This tailored approach allows for more effective treatment strategies that align with individual patient profiles, thereby improving overall outcomes. As awareness of genetic testing increases, more patients are being matched with appropriate therapies, maximizing treatment benefits. This trend towards personalized medicine optimizes cancer care and enhances the demand and utilization of PARP inhibitors in clinical settings, driving market growth.

Opportunities

• Advancement in Digital Health Solutions

The integration of digital health solutions, such as telemedicine and health monitoring apps, presents a significant market opportunity for enhancing the effectiveness of PARP inhibitor treatments. These technologies can improve patient engagement and adherence, crucial factors in treatment success. Telemedicine allows patients to consult healthcare providers from the comfort of their homes, facilitating timely follow-ups and personalized care without travel barriers. Health monitoring apps enable patients to track medication schedules, side effects, and overall health metrics, promoting accountability and proactive management of their treatment. By providing educational resources about PARP inhibitors, these digital tools empower patients and encourage adherence to prescribed regimens. This shift towards digital health enhances patient outcomes and creates a more supportive healthcare environment, creating new opportunities for market growth of PARP inhibitor therapies.

• Rising Awareness and Increasing Demand for PARP Inhibitors

Enhanced efforts by patient advocacy groups to raise awareness about genetic testing and targeted therapies significantly contribute to increasing demand for PARP inhibitors. By educating patients about the importance of genetic profiling, these organizations help individuals understand their risk for hereditary cancers and the potential benefits of targeted treatments. Initiatives such as community outreach, informational webinars, and collaboration with healthcare providers foster a more informed patient population. As awareness grows, more patients are likely to pursue genetic testing, which can identify those eligible for PARP inhibitor therapies. This proactive approach empowers patients to take charge of their health and drives the adoption of innovative cancer treatments, ultimately shaping a more effective oncology landscape.

Restraints/Challenges

• High Cost of Treatment

The significant expense associated with (PARP) inhibitors represents a major market challenge, limiting accessibility for many patients, particularly in regions with inadequate healthcare coverage. High treatment costs can deter patients from pursuing these effective therapies, leading to disparities in cancer care. In areas where insurance may not fully cover the expense of PARP inhibitors, patients are often faced with difficult choices, potentially opting for less effective treatments or forgoing therapy altogether. This situation is especially problematic in low-income populations, where financial constraints significantly impact healthcare access.

• Limited Clinical Evidence for Broad Indications

While PARP inhibitors have demonstrated effectiveness in treating specific cancers, such as ovarian and breast cancer, the lack of extensive clinical evidence supporting their use across a broader range of indications poses a significant market restraint. This limitation can hinder wider adoption of these therapies in clinical practice. Many healthcare providers rely on robust clinical trial data to inform treatment decisions, and the absence of comprehensive studies for other cancer types may lead to reluctance in prescribing PARP inhibitors outside established indications. Without sufficient evidence demonstrating their efficacy and safety in diverse patient populations, the potential benefits of PARP inhibitors remain underutilized, thereby restricting overall market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Scope

The market is segmented on the basis of drug type, indication type, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Talazoparib
• Veliparib
• Olaparib
• Others

Indication Type

• Ovarian Cancer
• Fallopian Tube Cancer
• Breast Cancer
• Others

End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

 Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Others

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, drug type, indication type, end users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is projected to lead the global Poly (ADP-Ribose) Polymerase (PARP) inhibitors market, driven by the presence of prominent key players in the industry. The region benefits from increased initiatives by local governments aimed at enhancing healthcare infrastructure and access. In addition, the availability of a skilled workforce is crucial for addressing the significant unmet medical needs among cancer patients. This combination of factors not only fosters innovation and research in the PARP inhibitors space but also strengthens market growth and expansion in North America.

Asia-Pacific region is anticipated to experience the highest growth rate from 2023 to 2030, driven by a rising geriatric population and increasing consumer awareness regarding health and wellness. As more individuals in this demographic seek effective treatment options, the demand for Poly (ADP-Ribose) Polymerase (PARP) inhibitors is likely to rise. In addition, efforts to improve healthcare access and education about cancer treatment options are further fueling this trend. This confluence of factors positions Asia-Pacific as a burgeoning market for PARP inhibitors, paving the way for significant advancements in cancer care and treatment accessibility.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Leaders Operating in the Market Are:

• Pfizer Inc. (U.S.)
• AstraZeneca (U.S.)
• Merck & Co. Inc. (U.S.)
• Myriad Genetics, Inc. (U.S.)
• GSK plc. (U.K.)
• Johnson & Johnson Services, Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)

Latest Developments in Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market

• 2023년 6월, 까다로운 암에 대한 방사성 약리학 혁신에 중점을 둔 사설 바이오테크 기업인 Ariceum Therapeutics는 Theragnostics Ltd.를 인수한다고 발표했습니다. 이 영국 기반 바이오제약 회사는 종양 진단 및 치료를 목표로 하는 방사성 표지 PARP 억제제 개발을 전문으로 합니다. 이 인수는 Ariceum의 포트폴리오를 강화하고 표적 암 치료의 발전을 가속화할 것으로 예상됩니다.

SKU-50391